Although selective targeting of BCL-xL may help to avoid the broader toxicities associated with dual BCL-2/BCL-xL inhibitors and provide a more precise therapeutic window to eliminate TIS cancer cells while sparing normal tissues, it could be argued that the BCL-xL-related platelet effect of A1331852 may complicate its clinical use. The gene discussed is BCL2L1; the disease is cancer.